Table 1 Univariate Analysis of Progression Free Survival and Overall Survival in 68 Stage IVb Thymic Carcinomas
Number (%) | Progression free survival P value | Overall survival P value | |
|---|---|---|---|
Age at diagnosis (years) | 52 (16–86) | 0.157 | 0.135 |
< 52 | 33 (48.5%) | ||
≥ 52 | 35 (51.5%) | ||
Sex | 0.647 | 0.753 | |
Male | 54 (79.4%) | ||
Female | 14 (20.6%) | ||
Histology | 0.135 | 0.454 | |
Squamous cell carcinoma | 46 (67.6%) | ||
Neuroendocrine carcinoma | 6 (8.8%) | ||
Adenocarcinoma | 4 (5.9%) | ||
Mucoepidermoid carcinoma | 1 (1.5%) | ||
Clear cell carcinoma | 1 (1.5%) | ||
Uncategorized | 10 (14.7%) | ||
Grading | 0.341 | 0.188 | |
G1 | 6 (13.1%) | ||
G2 | 11 (23.9%) | ||
G3 | 29 (63.0%) | ||
Myasthenia gravis | 0.523 | 0.033 | |
Yes | 2 (2.9%) | ||
No | 66 (97.1%) | ||
Tumor size | 9 (3–23)cm | 0.662 | 0.464 |
< 9 | 14 (20.6%) | ||
≥ 9 | 17 (25.0%) | ||
Unknown | 37 (54.4%) | ||
Metastasis | 0.054 | 0.002 | |
Lymphogenous | 43 (63.2%) | ||
Hematogenous | 25 (36.8%) | ||
Lymph node metastasis | 0.281 | 0.361 | |
Anterior lymph nodes | 10 (14.7%) | ||
Deep lymph nodes | 33 (48.5%) | ||
Hematogenous metastasis | 0.423 | 0.461 | |
Lung | 11 (16.2%) | ||
Bone | 4 (5.9%) | ||
Liver | 3 (4.4%) | ||
Adrenal gland | 1 (1.5%) | ||
Multiple organ | 6 (8.8%) | ||
Surgical Resection | 0.055 | 0.224 | |
Complete resection | 3 (4.4%) | ||
Incomplete resection | 28 (41.2%) | ||
Biopsy only | 37 (54.4%) | ||